Kevin joined MVM in 2016. Prior to MVM, he worked across the life science and healthcare sector as a consultant at Bain & Company. Kevin completed a BA in Natural Sciences and a PhD in Oncology at the University of Cambridge, where he conducted translational research in the field of neural development.

Kevin is a member of the board of Ossio and BioProtect, and previously represented MVM on the boards of Zipline Medical and Paragon 28

Latest news